Pharmaceutical Executive

• Pharmaceutical Executive Daily: FDA's Approval of Waskyra

  In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.

  --------  

  1:42

  --------

  1:42
• Pharmaceutical Executive Daily: FDA's New Standard for CAR-T Approvals

  In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novartis form a $1 billion multi-program collaboration targeting atopic diseases, and new insights reveal how payers are shaping expectations for Phase III trial design.

  --------  

  1:53

  --------

  1:53
• Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions

  In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed or refractory multiple myeloma, and Pfizer signs an exclusive collaboration with Yao Pharma to advance oral small-molecule GLP-1 agonists.

  --------  

  1:48

  --------

  1:48
• Pharmaceutical Executive Daily: FDA Approves Breyanzi

  In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a head-to-head Phase III trial against Imbruvica for CLL/SLL, and new analyses highlight how health systems are strengthening partnerships to support cell and gene therapy commercialization.

  --------  

  1:43

  --------

  1:43
• Pharmaceutical Executive Daily: Mark Cuban's Push for Generic Drug Fee Waivers

  In today’s Pharmaceutical Executive Daily, former FDA commissioners caution that new vaccine policies could weaken long-established regulatory standards, Mark Cuban urges federal officials to waive fees to boost generic drug competition, and a new report reveals patients are increasingly avoiding care due to rising healthcare costs.

  --------  

  1:48

  --------

  1:48

More Science podcasts

Trending Science podcasts

About Pharmaceutical Executive